Abstract
The bone marrow (BM) and the umbilical cord are the main sources of haematopoietic stem cells (HSCs) for the treatment of malignant and non-malignant haematologic diseases. The umbilical cord blood (UCB) is a source of choice of HSCs for unrelated allogeneic transplantation. The transplantation of UCB for treating patients with haematologic diseases is associated with delayed engraftment, graft failure and a high rate of mortality and morbidity, particularly in adults. Strategies are being devised and considered to improve the rate of success of UCB transplantation. Patients are treated with double dose of UCB. The fucosylation of UCB ex vivo, prior transplantation, improves the homing and engraftment of UCB stem cells to the BM in rodents. The improvement of the homing and engraftment of UCB stem cells to the BM would overcome the major limitations of UCB for transplantation for the treatment of haematologic diseases. It would reduce the delay of engraftment of UCB stem cells to the BM, reduce the risk of early infections and improve the rate of success of UCB transplantation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ballen KK, Barker JN, Stewart SK, Greene MF, Lane TA, American Society of Blood and Marrow Transplantation (2008) Collection and preservation of cord blood for personal use. Biol Blood Marrow Transplant 14:356–363
Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH (2007) Double unrelated reduced‐intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 13:82–89
Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG (2010) Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 16:287–291
Bengtson P, Lundblad A, Larson G, Påhlsson P (2002) Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins. J Immunol 169:3940–3946
Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder M, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein P, Randolph Broun E (1992) Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA 89:4109–4113
Cohen Y, Nagler A (2004) Umbilical cord blood transplantation: how, when and for whom? Blood Rev 18:167–179
De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV (2002) Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol 119:773–776
Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD (1998) Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci USA 95:14423–14428
Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, Cooper S, English D, Kurtzberg J, Bard J, Boyse EA (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilicalcord blood from an HLA-identical sibling. N Engl J Med 321:1174–1178
Grewal SS, Barker JN, Davies SM, Wagner JE (2003) Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 101:4233–4244
Hidalgo A, Frenette PS (2005) Enforced fucosylation of neonatal CD34+ cells generates selectin ligands that enhance the initial interactions with micro vessels but not homing to bone marrow. Blood 105:567–575
Hidalgo A, Weiss LA, Frenette PS (2002) Functional selectin ligands mediating human CD34+ cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Invest 110:559–569
Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS (2003) PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha 4 integrin. Blood 102:2060–2067
Keever CA, Abu-Hajir M, Graf W, McFadden P, Prichard P, O’Brien J, Flomenberg N (1995) Characterization of the alloreactivity and anti-leukaemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 15:407–419
Kelly SS, Parmar S, De Lima M, Robinson S, Shpall E (2010) Overcoming the barriers to umbilical cord blood transplantation. Cytotherapy 12:121–130
Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, Kapoor N, Guinan EC, Feig SA, Wagner EL, Kernan NA, COBLT Steering Committee (2008) Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112:4318–4327
Lapidot T, Dar A, Kollet O (2005) How do stem cells find their way home? Blood 106:1901–1910
Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood From unrelated donors. N Engl J Med 344:1815–1822
Long GD, Laughlin M, Madan B, Kurtzberg J, Gasparetto C, Morris A, Rizzieri D, Smith C, Vredenburgh J, Halperin EC, Broadwater G, Niedzwiecki D, Chao NJ (2009) Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 9:772–780
Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ (2006) Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 107:3804–3807
Martin PL, Carter SL, Kernan NA, Sahdev I, Wall D, Pietryga D, Wagner JE, Kurtzberg J (2006) Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant 12:184–194
Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH (1998) Hematopoietic progenitor cell rolling in bone marrow micro vessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 188:465–474
McEver RP (2002) Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 14:581–586
Michel G, Rocha V, Chevret S, Arcese W, Chan KW, Filipovich A, Takahashi TA, Vowels M, Ortega J, Bordigoni P, Shaw PJ, Yaniv I, Machado A, Pimentel P, Fagioli F, Verdeguer A, Jouet JP, Diez B, Ferreira E, Pasquini R, Rosenthal J, Sievers E, Messina C, Iori AP, Garnier F, Ionescu I, Locatelli F, Gluckman E, Eurocord Group (2003) Unrelated cord blood transplantation for childhood acute myeloid leukaemia: a Eurocord Group analysis. Blood 102:4290–4297
Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P (2000) Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predi than nucleated cell quantity. Blood 96:2717–2722
Potten CS, Loeffler M (1990) Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 110:1001–1020
Rocha V, Broxmeyer HE (2010) New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 16:S126–S132
Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR Berkowitz RL, Cabbad M, Dobrila NL, Taylor PE, Rosenfield RE, Stevens CE (1998) Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565–1577
Taupin P (2010a) Transplantation of cord blood stem cells for treating hematologic diseases and strategies to improve engraftment. Therapy 7:703–715
Taupin P (2010b) Ex vivo fucosylation of stem cells to improve engraftment: WO2004094619. Exp Opin Ther Patents 20:1265–1269
Taupin P (2010c) Ex vivo fucosylation to improve the engraftment capability and therapeutic potential of human cord blood stem cells. Drug Discovery Today 15:698–699
Taupin P (2011) Antibodies against CD20 (Rituximab) for treating multiple sclerosis: US 20100233121. Exp Opin Ther Patents 21(1):111–114
Wagner JE, Gluckman E (2010) Umbilical cord blood transplantation: the first 20 Years. Semin Hematol 47:3–12
Wang JC, Doedens M, Dick JE (1997) Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89:3919–3924
Wang XN, Sviland L, Ademokun AJ, Dunn J, Cavanagh G, Proctor SJ, Dickinson AM (1998) Cellular alloreactivity of human cord blood cells detected by T-cell frequency analysis and a human skin explant model. Transplantation 66:903–909
Weninger W, Ulfman LH, Cheng G, Souchkova N, Quackenbush EJ, Lowe JB, von Andrian UH (2000) Specialized contributions by alpha(1,3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal micro vessels. Immunity 12:665–676
Xia L, McDaniel JM, Yago T, Doeden A, McEver RP (2004) Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 104:3091–3096
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Taupin, P. (2012). Umblical Cord Blood and Alpha-3 Fucosyl Transferase-Treated Haematopoietic Stem Cells for Transplantation. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 1. Stem Cells and Cancer Stem Cells, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1709-1_19
Download citation
DOI: https://doi.org/10.1007/978-94-007-1709-1_19
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-1708-4
Online ISBN: 978-94-007-1709-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)